About the Company
We do not have any company description for Voyager Acquisition Corp./Cayman Islands at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Voyager Acquisition Corp./Cayman Islands
Voyager Acquisition Corp. Announces Pricing of $220,000,000 ... - Nasdaq
BROOKLYN, N.Y., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Voyager Acquisition Corp. (Nasdaq: VACHU) (the “Company”) announced today the pricing of its initial public offering of 22,000,000 units at ...
Voyager Acquisition Corp. Announces Pricing of $220,000,000 Initial ...
BROOKLYN, N.Y., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Voyager Acquisition Corp. (Nasdaq: VACHU) (the “Company”) announced today the pricing of its initial public offering of 22,000,000 units at ...
Voyager Acquisition Corp. Announces Closing of $253,000,000 Initial ...
BROOKLYN, N.Y., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Voyager Acquisition Corp. (Nasdaq: VACHU) (the “Company”) today announced that it closed its initial public offering of 25,300,000 units at ...
Voyager Acquisition Corp. Announces the Separate Trading of its Class A ...
BROOKLYN, N.Y., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Voyager Acquisition Corp. (Nasdaq: VACHU) (the “Company”) announced that holders of the units sold in the Company’s initial public offering ...
VERAXA Biotech and Voyager Acquisition Corp. Announce Filing of Form F ...
ZURICH, SWITZERLAND, July 17, 2025 -- VERAXA Biotech AG (“VERAXA” or the "Company"), an emerging leader in designing novel cancer therapies, and Voyager Acquisition Corp., a Cayman Islands ...
VERAXA Biotech and Voyager Acquisition Corp. Announce Business ...
ZURICH, SWITZERLAND, and BROOKLYN, NEW YORK, USA, April 23, 2025 --VERAXA Biotech AG (“VERAXA” or the “Company”), an emerging leader in designing novel cancer therapies, and Voyager ...
Similar Companies
Loading the latest forecasts...